| dc.contributor.author | Akande, Oluwatosin Wuraola | |
| dc.contributor.author | Igumbor, Ehimario Uche | |
| dc.contributor.author | Elimian, Kelly Osezele | |
| dc.date.accessioned | 2022-08-16T07:25:31Z | |
| dc.date.available | 2022-08-16T07:25:31Z | |
| dc.date.issued | 2022 | |
| dc.identifier.citation | Akande, O. W. et al. (2022). Covid-19 vaccine effectiveness studies in Nigeria: Quo vadis?. Journal of global health, 12, 03055. 10.7189/jogh.12.03055 | en_US |
| dc.identifier.issn | 2047-2986 | |
| dc.identifier.uri | 10.7189/jogh.12.03055 | |
| dc.identifier.uri | http://hdl.handle.net/10566/7735 | |
| dc.description.abstract | The “lickety-split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was
first sequenced is indeed one of the public health successes of the 21st century. Particularly because an
18-month target was initially considered reasonable, and having achieved this success, a “moonshot”
goal to ensure that a vaccine is available within 100 days after the next pandemic pathogen is recognized has
been set [1]. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | International Society of Global Health | en_US |
| dc.subject | Covid-19 | en_US |
| dc.subject | Public health | en_US |
| dc.subject | Vaccine | en_US |
| dc.subject | Nigeria | en_US |
| dc.subject | World Health Organisation (WHO) | en_US |
| dc.title | Covid-19 vaccine effectiveness studies in Nigeria: Quo vadis? | en_US |
| dc.type | Article | en_US |
